Press Releases September 15, 2026 07:00 PM

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Carlsmed Files Patent Infringement Lawsuit Against DeGen Medical to Protect AI-Enabled Spine Surgery Innovations

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CARL

Carlsmed, Inc., a Nasdaq-listed medical technology company specializing in AI-driven personalized spine surgery solutions, has filed a patent infringement lawsuit against DeGen Medical, alleging unauthorized use of eight of its patents related to implants, methods, and systems. The company seeks injunctive relief and damages to protect its intellectual property and maintain its competitive edge in the spine surgery industry.

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
CARL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Carlsmed initiated legal proceedings in U.S. District Court alleging patent infringement by DeGen Medical involving eight patents.
  • The patents in question pertain to implants, methods, and systems integral to Carlsmed's personalized spine surgery technology.
  • Carlsmed emphasizes its commitment to protecting its intellectual property to sustain innovation and leadership in AI-enabled spine surgery solutions.

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.

The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement.

“Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing value to patients, surgeons, and payors every day. We are committed to protecting the intellectual property that supports our patient-centric innovation, which remains at the forefront of the industry,” said Mike Cordonnier, Chairman and CEO of Carlsmed.

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed’s ability to scale its business and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations
[email protected]

Media
[email protected]


Risks

  • Legal outcomes are uncertain and may involve significant costs affecting financial performance and resources.
  • Potential delays or disruptions in product development or commercialization may arise if the lawsuit impacts operations.
  • Patent infringement disputes could affect partnerships and market perception within the medical device and healthcare sectors.

More from Press Releases

UniFirst Declares Increased Cash Dividends Oct 30, 2026 Orange County Bancorp, Inc. Announces Record Third Quarter Earnings Oct 28, 2026 ARMOUR Residential REIT, Inc. Announces Q3 Results And September 30, 2026 Financial Position Oct 21, 2026 Eagle Bancorp, Inc. Announces Third Quarter 2026 Results Oct 21, 2026 iPower Opens New AI Era with Five-Year Services LOI Targeting $21.90 Million in Potential Annualized Services Oct 15, 2026